Inventiva S.A [IVA] vs Nanobiotix [NANO] Detailed Stock Comparison

Inventiva S.A

Euronext
Loading...

Nanobiotix

Euronext
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Inventiva S.A wins in 6 metrics, Nanobiotix wins in 9 metrics, with 1 ties. Nanobiotix appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricInventiva S.ANanobiotixBetter
P/E Ratio (TTM)-1.54-5.90Nanobiotix
Price-to-Book Ratio-1.72N/AN/A
Debt-to-Equity Ratio-1.70-0.77Inventiva S.A
PEG Ratio-3.34-7.81Nanobiotix
EV/EBITDA-5.57-5.88Nanobiotix
Profit Margin (TTM)0.00%0.00%Tie
Operating Margin (TTM)-384.43%271.42%Nanobiotix
EBITDA Margin (TTM)N/A271.42%N/A
Return on Equity172.73%103.70%Inventiva S.A
Return on Assets (TTM)-63.60%-52.89%Nanobiotix
Free Cash Flow (TTM)$-86.26M$-20.40MNanobiotix
1-Year Return185.54%146.25%Inventiva S.A
Price-to-Sales Ratio (TTM)46.08-56.45Nanobiotix
Enterprise Value$522.47M$397.94MInventiva S.A
EV/Revenue Ratio37.07-55.35Nanobiotix
Revenue per Share (TTM)$0$0Inventiva S.A
Earnings per Share (Diluted)$-3.08$-1.44Nanobiotix
Beta (Stock Volatility)0.741.58Inventiva S.A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Inventiva S.A vs Nanobiotix Stock Performance Analysis

Loading Price Chart...

Inventiva S.A
Nanobiotix
Inventiva S.A Stock Overview | Nanobiotix Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Inventiva S.A1.39%7.48%17.62%74.26%71.74%124.64%
Nanobiotix3.23%35.45%45.20%205.85%240.24%274.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Inventiva S.A185.54%30.22%-54.86%-42.82%-42.82%-42.82%
Nanobiotix146.25%215.07%82.25%-29.79%85.48%85.48%

News Based Sentiment: Inventiva S.A vs Nanobiotix

Inventiva S.A

News based Sentiment: MIXED

September presented a mixed bag for Inventiva, with positive analyst upgrades and active investor engagement countered by downward revisions to revenue estimates and stock price fluctuations. The company's progress in clinical trials and potential as an acquisition target add complexity to the investment picture, making it a high-risk, high-reward opportunity.

View Inventiva S.A News Sentiment Analysis

Nanobiotix

News based Sentiment: POSITIVE

September was a pivotal month for Nanobiotix, driven by highly encouraging Phase 1 trial results for NBTXR3 in melanoma and a strategic partnership with Janssen that significantly extended the company's cash runway. These developments spurred a substantial increase in the stock price and positive analyst revisions, indicating a strengthened investment case, though some caution remains.

View Nanobiotix News Sentiment Analysis

Performance & Financial Health Analysis: Inventiva S.A vs Nanobiotix

MetricIVANANO
Market Information
Market Cap i€658.45M€416.19M
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i229,057150,322
90 Day Avg. Volume i287,655223,562
Last Close€4.74€11.50
52 Week Range€1.43 - €5.26€2.62 - €11.54
% from 52W High-9.98%-0.35%
All-Time High€16.30 (Jan 18, 2021)€33.12 (Feb 10, 2014)
% from All-Time High-70.92%-65.28%
Growth Metrics
Quarterly Revenue Growth-0.30%N/A
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-3.84%2.71%
Return on Equity (TTM) i1.73%1.04%
Debt to Equity (MRQ) i-1.70-0.77
Cash & Liquidity
Book Value per Share (MRQ)€-1.12€-1.39
Cash per Share (MRQ)€1.01€1.05
Operating Cash Flow (TTM) i€-85,928,000€-19,551,000
Levered Free Cash Flow (TTM) i€-56,252,248€-33,155,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Inventiva S.A vs Nanobiotix

MetricIVANANO
Price Ratios
P/E Ratio (TTM) i-1.54-5.90
Forward P/E i-3.34-7.81
PEG Ratio i-3.34-7.81
Price to Sales (TTM) i46.08-56.45
Price to Book (MRQ) i-1.72N/A
Market Capitalization
Market Capitalization i€658.45M€416.19M
Enterprise Value i€522.47M€397.94M
Enterprise Value Metrics
Enterprise to Revenue i37.07-55.35
Enterprise to EBITDA i-5.57-5.88
Risk & Other Metrics
Beta i0.741.58
Book Value per Share (MRQ) i€-1.12€-1.39

Financial Statements Comparison: Inventiva S.A vs Nanobiotix

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)IVANANO
Revenue/Sales i€65,000N/A
Cost of Goods Sold iN/AN/A
Gross Profit iN/AN/A
Research & Development i€11.91MN/A
Operating Income (EBIT) i€-13.67MN/A
EBITDA i€-13.43MN/A
Pre-Tax Income i€-14.27MN/A
Income Tax i€21,000N/A
Net Income (Profit) i€-14.30MN/A

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)IVANANO
Cash & Equivalents i€96.56M€49.74M
Total Current Assets i€111.51M€61.47M
Total Current Liabilities i€120.73M€58.94M
Long-Term Debt i€48.46M€45.98M
Total Shareholders Equity i€-106.65M€-65.70M
Retained Earnings i€-184.21M€-68.13M
Property, Plant & Equipment i€10.72M€2.49M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)IVANANO
Operating Cash Flow i€-24.55MN/A
Capital Expenditures i€-63,000N/A
Free Cash Flow i€-12.13MN/A
Debt Repayment i€-1,000N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricIVANANO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i229,057150,322
Average Daily Volume (90 Day) i287,655223,562
Shares Outstanding i95.66M47.40M
Float Shares i50.52M24.81M
% Held by Insiders i0.08%0.15%
% Held by Institutions i0.69%0.28%

Dividend Analysis & Yield Comparison: Inventiva S.A vs Nanobiotix

MetricIVANANO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A